Nugent, D;
Gilson, R;
(2017)
Where next with preexposure prophylaxis?
Current Opinion in Infectious Diseases
, 30
(1)
pp. 44-49.
10.1097/QCO.0000000000000340.
Preview |
Text
Gilson_Where next with preexposure prophylaxis.pdf - Accepted Version Download (462kB) | Preview |
Abstract
Purpose of review: Controlling the HIV epidemic remains a major public health challenge, and there is an urgent need for novel prevention strategies. Preexposure prophylaxis (PrEP) refers to the use of antiretrovirals in HIV-negative people at high risk to prevent infection and has the potential to be an important component in the global effort to end the HIV epidemic by 2030. We review the current evidence for the safety and efficacy of PrEP in its different forms and address emergent issues and concerns regarding its implementation. / Recent findings: Two further randomized control trials report high efficacy of both daily and intermittent PrEP in MSM leading to renewed calls for wider availability of PrEP for this group. Oral tenofovir disoproxil/emtricitabine has been licensed for PrEP in many countries and is well tolerated, safe and effective. / Summary: Oral PrEP is well tolerated and effective in reducing the incidence of HIV infection in individuals at high risk. Implementation in high-income countries is progressing slowly; demonstration projects and trials continue in low and middle-income countries.
| Type: | Article |
|---|---|
| Title: | Where next with preexposure prophylaxis? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/QCO.0000000000000340 |
| Publisher version: | http://doi.org/10.1097/QCO.0000000000000340 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Infectious Diseases, Hiv Prevention, Hiv Transmission, Preexposure Prophylaxis, Tenofovir Disoproxil Fumarate, Hiv Prevention, Antiretroviral Prophylaxis, Immunodeficiency-virus, Cost-effectiveness, Bangkok Tenofovir, Renal-function, African Women, Phase-3 Trial, Double-blind |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1531774 |
Archive Staff Only
 |
View Item |
